EP1304110A2 — Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
Assigned to Glaxo Group Ltd · Expires 2003-04-23 · 23y expired
What this patent protects
Protein tyrosine kinase inhibitor compounds are described, as are methods for their preparation, pharmaceutical compositions including such compounds, and their use in medicine, for example in the treatment of cancer and psoriasis. In particular, the use of an inhibitor of both E…
USPTO Abstract
Protein tyrosine kinase inhibitor compounds are described, as are methods for their preparation, pharmaceutical compositions including such compounds, and their use in medicine, for example in the treatment of cancer and psoriasis. In particular, the use of an inhibitor of both EGFR and erbB-2 in the treatment of a susceptible malignancy, such as cancer or a malignant tumour, is described.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.